Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Giant Biogene Holding Co. Ltd. ( (HK:2367) ).
Giant Biogene Holding Co., Ltd., a Hong Kong-listed biotechnology group, focuses on bio-based products and related life sciences technologies, and prepares audited consolidated financial statements in accordance with IFRS. The company operates through its subsidiaries and is overseen by a board and audit committee that review its annual performance and compliance.
For the year ended 31 December 2025, the group reported broadly flat revenue of RMB5,518.5 million but saw net profit decline 7.1% to RMB1,914.7 million, with earnings per share falling more than 12%. Despite softer profitability amid higher costs and expenses, the board proposed both a final and a special dividend per share, signalling continued confidence in cash generation and offering income support to shareholders even as margins came under pressure.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd. is a Hong Kong-listed biotechnology company operating through subsidiaries, with its shares traded under stock code 2367. The group develops and sells bio-based products and related technologies, positioning itself within the broader life sciences and biopharmaceuticals sector, and reports its consolidated results under IFRS Accounting Standards.
Average Trading Volume: 5,282,517
Technical Sentiment Signal: Sell
Current Market Cap: HK$34.2B
For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.